Achieve Life Sciences, Inc. (ACHV)
Achieve Life Sciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of smoking cessation and other neuropsychiatric conditions. The company is known for its research and development efforts in psychedelics and innovative medications aimed at addressing addiction and mental health issues.
Company News
Achieve Life Sciences completed a public offering of 15 million shares and accompanying warrants, raising $45 million to fund the development of cytisinicline, a potential treatment for nicotine dependence and smoking cessation.
Achieve Life Sciences plans a public offering to raise funds for advancing cytisinicline, a potential treatment for nicotine dependence and smoking cessation, after submitting a New Drug Application to the FDA in June 2025.
The following new investment ideas were made by analysts who have NO OTHER Buy/Strong Buy recommendations in the past 3 months. Check out the picks for April 2024.